MedTrace Logo

Cardiac Symptoms in Patients With Treated Graves' Disease

NCT06908369 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-04-03

No results posted yet for this study

Summary

Hyperthyroidism is a condition with increased production of thyroid hormone from the thyroid gland. Hyperthyroidism affects the heart's inotropy (contractile force) and chronotropy (rhythm). Therefore, patients often experience symptoms such as increased/irregular heart rate, pounding heartbeats, and shortness of breath. The cardiac symptoms often improve when hyperthyroidism is treated and biochemical euthyroidism is achieved. However, knowledge of the long-term effects on the heart is limited. Existing studies have generally shown that patients with hyperthyroidism have an increased morbidity and mortality.

The investigators conducted a questionnaire survey which showed that about 38% of patients with Graves' disease continue to experience cardiac symptoms even months after normalization of thyroid hormone concentrations in the blood. This observation supports the presence of a persistent cardiovascular dysfunction, which may be due to a modulation of genomic or non-genomic factors with an effect on the cardiovascular system. These reflections are the focus of this clinical study. The aim of the study is to investigate the possible pathophysiology for this new "syndrome" in biochemically euthyroid patients. It is not a repetition of previous similar experiments.

Conditions

Sponsors & Collaborators

  • Ulla Feldt-Rasmussen

    lead OTHER

Principal Investigators

  • Ulla Feldt-Rasmussen, MD; DMSc · Rigshospitalet, Denmark

  • Stig Haunsø, MD; DMSc · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2025-07-20
Completion
2025-10-15

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06908369 on ClinicalTrials.gov